Atharva Karulkar

Indian Institute of Technology Bombay — India

Medicine · Health Sciences

10h-index390citations37works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(22), Biosimilars and Bioanalytical Methods(8), Cutaneous lymphoproliferative disorders research(6), Lymphoma Diagnosis and Treatment(4), Virus-based gene therapy research(3)

Publications37 total

Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access
Blood·2025Open Access
Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.
Blood·2025Open Access
A multicentre Phase I clinical trial demonstrates manufacturing feasibility, safety and activity of novel humanized BCMA-directed CAR-T cell therapy.
Blood·2025
POSTER: CT-1080 Incidence, Clinical Characteristics, and Risk Factors of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IECHS) in Patients Treated With Talicabtagene Autoleucel (Humanized Anti-CD19 CAR-T)
Clinical Lymphoma Myeloma & Leukemia·2025
CT-1080: Incidence, Clinical Characteristics, and Risk Factors of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS) in Patients Treated With Talicabtagene Autoleucel (Humanized Anti-CD19 CAR-T)
Clinical Lymphoma Myeloma & Leukemia·2025
Correction: Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study
Blood Cancer Journal·2025Open Access
Implementation of a CAR-T cell therapy program in India
Expert Review of Anticancer Therapy·2025· 4 cited
Development of equitable access model for nationwide implementation of affordable CAR-T cell therapy in India: a real-world experience.
Cytotherapy·2025· 1 cited
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study
Blood Cancer Journal·2025· 7 citedOpen Access
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study
The Lancet Haematology·2025· 8 cited
Cellular Therapies: From a Theoretical Concept to an Immuno-augmented Reality
2025
Talicabtagene Autoleucel (humanized CD19 CAR-T) As a Second Line Therapy in r/r B-Cell Lymphoma: Sub-Analysis from a Phase I/II Trial
Blood·2024· 2 citedOpen Access
Development of a Novel Humanized BCMA-Directed CAR for Multiple Myeloma: Robust Activity and Low Toxicity in Preclinical Studies
Blood·2024· 1 citedOpen Access
Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile
Blood·2024· 5 cited
An Analysis of Infectious Complications Post-Treatment With Actalycabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2024
CT-643 An Analysis of Infectious Complications Post-Treatment With Actalycabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility
Blood·2023· 2 citedOpen Access
High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial
Blood·2023· 12 cited
<i>E</i>valuating the <i>S</i>afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel <i>H</i>umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B
Blood·2023· 6 cited
Data from The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Rahul Purwar(37), Bhausaheb Bagal(20), Manju Sengar(19), Hasmukh Jain(18), Shreshtha Shah(16), Afrin Firfiray(15), Juber Pendhari(15), Smrithi Ravikumar(15), Lingaraj Nayak(15), Alka Dwivedi(14), Devanshi Kalra(14), Ankesh Kumar Jaiswal(13), Nirali N. Shah(13), Prashant Tembhare(12), Aalia Khan(11), Sweety Asija(11), Gaurav Narula(10), Alok Shetty(9), Sarbari Ghosh(8), Sridhar Epari(8)